-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HxIohBj5lDDeOKFbG9q41ZK9zprej2yINODZYO6D3SZIcvN3/31NnB/Sn6qL37cc KVPTdgfpm0wXErdz5nEUqw== 0000950162-03-001014.txt : 20030715 0000950162-03-001014.hdr.sgml : 20030715 20030715150049 ACCESSION NUMBER: 0000950162-03-001014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030715 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 03787101 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 shire8k071503.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2003 Shire Pharmaceuticals Group plc ________________________________________________________________________________ (Exact name of registrant as specified in its charter) England and Wales ________________________________________________________________________________ (State or other jurisdiction of incorporation) 0-29630 98-0359573 (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England ________________________________________________________________________________ (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44 1256 894 000 ________________________________________________________________________________ (Former name or former address, if changed since last report) Item 5. Other Events Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and incorporated by reference herein. Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Press Release dated July 15, 2003 -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 15, 2003 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ Angus Charles Russell ------------------------------- Name: Angus Charles Russell Title: Group Finance Director EXHIBIT INDEX Number Description 99.1 Press Release dated July 15, 2003 EX-99.1 3 shire8k071503ex991.txt PRESS RELEASE Q2 2003 RESULTS PRESENTATION - 31 July 2003 Basingstoke, UK - 15 July 2003 - Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce second quarter 2003 earnings on Thursday, 31 July 2003. Results announcement time: 12:00 BST / 07:00 ET Conference call time: 14:00 BST / 09:00 ET Live conference call: The details of the live conference call are as follows: UK dial in + 44 1452 542 304 US / Canada dial in 1866 389 9780 Password Shire Pharmaceuticals Live audio webcast: There will also be a live audio webcast available, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website. Replay: A replay of the presentation will be available for 2 weeks. Details are as follows: ----------------------------------------- ------------------------------------ UK International no: + 44 (0)1452 55 00 00 ----------------------------------------- ------------------------------------ UK PIN (access) no: 321825# ----------------------------------------- ------------------------------------ US no: 1866 276 1167 ----------------------------------------- ------------------------------------ US PIN (access) no: 321825# ----------------------------------------- ------------------------------------ Webcast Replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894 160 End For further information please contact: Global Investor Relations Clea Rosenfeld +44 (0)1256 894 160 North America Investor Relations Gordon Ngan +44 (0)1256 894 160 Notes to editors Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international emerging pharmaceutical company with a strategic focus on four therapeutic areas - - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and anti-infectives. Shire also has three platform technologies: advanced drug delivery, lead optimisation for small molecules and Biologics. Shire's core strategy is based on research and development combined with in-licensing and a focus on key pharmaceutical markets. For further information on Shire, please visit the Company's website: www.shire.com THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. Statements included herein that are not historical facts, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialise, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialisation, the impact of competitive products, including, but not limited to, the impact on Shire's Attention Deficit Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire's ADHD franchise, government regulation and approval, including but not limited to the expected product approval date of lanthanum carbonate (FOSRENOL(R)) and METHYPATCH (R) , and other risks and uncertainties detailed from time to time in our filings, including the Annual Report filed on Form 10-K by Shire with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----